PDE5A and pulmonary arterial hypertension: The development of PDE5 inhibitors, such as sildenafil, are effective pharmacological agents for the treatment of patients with PAH due to either ability to bind to the PDE5 enzyme, inhibit the breakdown of cGMP and thereby prolong the effect of endogenous NO (Figure 7)88.